RxDoctor Payments Data

Justin Karl, MD

Cardiovascular Disease · Lawrenceville, NJNPI 1134366958

Payments from drug & device makers

$7,313in general payments, 2019–2025

Across 450 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$879
  • Amgen$735
  • Johnson & Johnson$647
  • Boston Scientific$621
  • E.r. Squibb & Sons, L.L.C.$437
  • AOP Health US, LLC$336
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,21099%
  • Education$1031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,313 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$262,870
Medicare patients
895
Services billed
3,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$199,977
EntrestoSacubitril/Valsartan54$76,974
Repatha SureclickEvolocumab28$39,099
JardianceEmpagliflozin39$38,435
XareltoRivaroxaban30$35,821
BrilintaTicagrelor25$18,443
Praluent PenAlirocumab19$15,253
Rosuvastatin Calcium288$4,224
Atorvastatin Calcium259$3,060
Metoprolol Succinate155$2,913
Amlodipine Besylate290$1,906
Metoprolol Tartrate227$1,843
Valsartan38$1,760
Ezetimibe65$1,479
Amiodarone Hcl21$1,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$302$199,977156 claims
NovartisEntresto$879$76,97454 claims
Boehringer IngelheimJardiance$246$38,43539 claims
Johnson & JohnsonXarelto$647$35,82130 claims
AstraZenecaBrilinta$271$18,44325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Lawrenceville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →